ADVI Expert Discusses Medicare Drug Pricing Negotiation’s “Spillover Effect” With AIS Health
On September 1, 2023, ADVI’s
Lindsay Bealor Greenleaf, vice president and head of policy and reimbursement, shared her insights on the first ten drugs on the Medicare negotiation list and what “spillover effect” or impact these negotiations will have on the commercial insurance market. Read more about Lindsay’s insights and predictions
here.